Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management
created opportunities for comprehensive diabetes care. Two classes of drugs, GLP1RA (glucagon-like peptide 1 receptor agonists), and SGLT2i (sodium glucose cotransporter 2 inhibitors) have demonstrated their efficacy in glucose control as well as cardiovascular risk reduction. While both can be use...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Pakistan Medical Association
2022-05-01
|
Series: | Journal of the Pakistan Medical Association |
Online Access: | https://www.ojs.jpma.org.pk/index.php/public_html/article/view/7020 |